Filing Flows › Biomerica (BMRA) › Q4 FY26
Biomerica (BMRA) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Aug 31, 2026
Biomerica (BMRA) reported revenue of $875K for the fourth quarter fiscal 2026 (Q4 FY26), +17% from a year earlier and -11% from the quarter before. Operating margin was -175.2%, net loss $1.1M (130.9% of revenue).
Biomerica, Q4 FY26: revenue $875K (+17% year over year), operating margin -175.2%, net loss $1.1M, operating cash flow −$912K. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $875K | -11% | +17% |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$1.1M | — | — |
| Operating cash flow | −$912K | — | — |
What changed
Revenue was $875K in Q4 FY26, up 17% year over year and down 11% from the previous quarter. Clinical Lab was the largest line at 47% of revenue.
Operating costs exceeded revenue by $1.5M, an operating margin of -175.2%. Total costs grew 4% against revenue growth of 17%. The fastest-growing cost line was General & admin (+27%). The quarter ended with a net loss of $1.1M, narrower than the previous quarter's $1.3M loss. Non-operating items added $394K, -35% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$912K. Non-cash charges added back $17K of depreciation and amortization and $91K of share-based compensation. Working capital and other items added $125K.
Questions
What was Biomerica's revenue in the fourth quarter fiscal 2026?
Biomerica (BMRA) reported revenue of $875K for the fourth quarter fiscal 2026 (Q4 FY26), +17% from a year earlier and -11% from the quarter before.
Was Biomerica profitable in the fourth quarter fiscal 2026?
Operating loss was $1.5M (-175.2% of revenue) and net loss $1.1M.
Source: Biomerica 10-K on SEC EDGAR.